IL163884A0 - Treatment of central nervous systemdamage - Google Patents

Treatment of central nervous systemdamage

Info

Publication number
IL163884A0
IL163884A0 IL16388403A IL16388403A IL163884A0 IL 163884 A0 IL163884 A0 IL 163884A0 IL 16388403 A IL16388403 A IL 16388403A IL 16388403 A IL16388403 A IL 16388403A IL 163884 A0 IL163884 A0 IL 163884A0
Authority
IL
Israel
Prior art keywords
systemdamage
treatment
central nervous
cns
mammal
Prior art date
Application number
IL16388403A
Other languages
English (en)
Original Assignee
King S College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King S College London filed Critical King S College London
Publication of IL163884A0 publication Critical patent/IL163884A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Purification Treatments By Anaerobic Or Anaerobic And Aerobic Bacteria Or Animals (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
IL16388403A 2002-03-04 2003-03-04 Treatment of central nervous systemdamage IL163884A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0205022.7A GB0205022D0 (en) 2002-03-04 2002-03-04 Materials and methods for the treatment of cns damage
PCT/GB2003/000901 WO2003074080A1 (en) 2002-03-04 2003-03-04 Treatment of central nervous system damage

Publications (1)

Publication Number Publication Date
IL163884A0 true IL163884A0 (en) 2005-12-18

Family

ID=9932221

Family Applications (3)

Application Number Title Priority Date Filing Date
IL16388403A IL163884A0 (en) 2002-03-04 2003-03-04 Treatment of central nervous systemdamage
IL163884A IL163884A (en) 2002-03-04 2004-09-02 Preparation of medicaments to promote neuronal plasticity
IL223875A IL223875A (en) 2002-03-04 2012-12-25 Use of chondroitinase in the preparation of a drug for use in a method of promoting neural flexibility

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL163884A IL163884A (en) 2002-03-04 2004-09-02 Preparation of medicaments to promote neuronal plasticity
IL223875A IL223875A (en) 2002-03-04 2012-12-25 Use of chondroitinase in the preparation of a drug for use in a method of promoting neural flexibility

Country Status (15)

Country Link
US (1) US20050118157A1 (de)
EP (2) EP1480674B1 (de)
JP (2) JP5112607B2 (de)
AT (1) ATE490786T1 (de)
AU (2) AU2003208466B2 (de)
CA (1) CA2478645C (de)
DE (1) DE60335244D1 (de)
DK (1) DK1480674T3 (de)
ES (1) ES2357227T3 (de)
GB (1) GB0205022D0 (de)
IL (3) IL163884A0 (de)
MX (1) MXPA04008598A (de)
PT (1) PT1480674E (de)
SI (1) SI1480674T1 (de)
WO (1) WO2003074080A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001253408C1 (en) * 2000-04-13 2008-12-04 Mervyn Merrilees Therapeutic compounds and methods for formulating V3, A Versican Isoform
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
EP2301564A1 (de) * 2002-05-04 2011-03-30 Acorda Therapeutics, Inc. Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
DE60334220D1 (de) 2002-06-03 2010-10-28 Massachusetts Inst Technology Rationell konstruierte, von chondroitinase b abgeleitete lyasen
US20060153827A1 (en) * 2002-08-15 2006-07-13 Gruskin Elliott A Chimeric protein
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
CA2864810A1 (en) 2003-04-18 2004-11-04 Biogen Idec Ma, Inc. Polymer-conjugated glycosylated neublastin
WO2004110359A2 (en) * 2003-05-16 2004-12-23 Acorda Therapeutics, Inc. Fusion proteins for the treatment of cns
JP4754492B2 (ja) * 2003-05-16 2011-08-24 アコーダ セラピューティクス、インク． 中枢神経系障害を治療するための組成物および方法
EP3514238B1 (de) 2003-05-16 2021-05-05 Acorda Therapeutics, Inc. Proteoglycan-abbauende mutanten zur behandlung des zns
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
EP1737954A2 (de) 2004-03-10 2007-01-03 The Massachusetts Institute Of Technology Rekombinante chondroitinase abc i und verwendungen davon
US8226941B2 (en) 2004-05-18 2012-07-24 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
BRPI0514534A (pt) * 2004-08-19 2008-06-17 Biogen Idec Inc variantes de neublastina
NZ553420A (en) 2004-08-19 2010-02-26 Biogen Idec Inc Refolding transforming growth factor beta family proteins
JP2008545705A (ja) * 2005-05-25 2008-12-18 ザ・ジョンズ・ホプキンス・ユニバーシティ 軸索再生を促進する組成物及び方法
JP5189985B2 (ja) 2005-09-26 2013-04-24 アコーダ セラピューティクス、インク． コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法
TWI501774B (zh) * 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
EP1993590B1 (de) * 2006-03-01 2013-12-25 Biogen Idec MA Inc. Zusammensetzungen und verfahren zur verabreichung von proteinen der gdnf-liganden-familie
WO2008029493A1 (fr) * 2006-09-08 2008-03-13 Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. Inhibiteur de dégénération de fibres nerveuses
US7722864B2 (en) 2006-10-10 2010-05-25 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
JP5583005B2 (ja) 2007-05-01 2014-09-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管新生を増大させるための組成物および方法
WO2008149428A1 (ja) * 2007-06-05 2008-12-11 Glycoscience Laboratories, Inc. 自己免疫疾患、炎症及び神経疾患の治療剤及び予防剤
WO2009020964A2 (en) * 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
WO2009061368A1 (en) * 2007-11-06 2009-05-14 Benaroya Research Institute Inhibition of versican with sirna and other molecules
GB0723825D0 (en) * 2007-12-05 2008-01-23 Ucl Business Plc Composition
WO2009128446A1 (ja) * 2008-04-14 2009-10-22 国立大学法人名古屋大学 神経因性疼痛の改善剤
EP2153844A1 (de) * 2008-08-14 2010-02-17 HAUBECK, Hans-Dieter Humane Hyaluronidasen zum erneuten axonalen Wachstum
US20110311521A1 (en) 2009-03-06 2011-12-22 Pico Caroni Novel therapy for anxiety
US20110124706A1 (en) * 2009-11-25 2011-05-26 Zhigang He SOCS3 Inhibition Promotes CNS Neuron Regeneration
JP5885136B2 (ja) * 2011-01-31 2016-03-15 学校法人 愛知医科大学 高硫酸化コンドロイチン硫酸類の合成方法、高硫酸化コンドロイチン硫酸類、および解析用試薬
WO2012136768A1 (en) 2011-04-08 2012-10-11 Hans-Dieter Haubeck Use of mutants of human hyaluronidase ph-20 with increased chondroitinase activity for axonal regrowth
EP2773382A4 (de) 2011-11-01 2016-03-23 Childrens Medical Center Gleichzeitige aktivierung von mtor- und stat3-pfaden zur förderung von neuronalem überleben und regeneration
US20150274815A1 (en) * 2012-09-25 2015-10-01 The United States of America, as represented by the Secretary, Department of Health & Human Servic Treatment of central nervous system (cns) injury
WO2014065669A1 (en) * 2012-10-26 2014-05-01 Stichting Vu-Vumc Methods of treatment and diagnosis for cognitive decline and memory impairment
EP3033416A4 (de) * 2013-08-12 2017-02-08 Benaroya Research Institute at Virginia Mason 4-methylumbelliferon-behandlung zur immunmodulation
WO2018029685A1 (en) * 2016-08-11 2018-02-15 Technion Research & Development Foundation Limited Compositions and methods for treating a fear memory

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU6872691A (en) * 1989-10-27 1991-05-31 Case Western Reserve University Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans
JPH06502840A (ja) * 1989-10-27 1994-03-31 ケース ウェスタン リザーブ ユニバーシティ ケラタン硫酸、コンドロイチン硫酸、デルマタン硫酸及び他のグリカンによる細胞成長の阻害
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5496718A (en) 1992-06-26 1996-03-05 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Chondroitinase ABC isolated from proteus vulgaris ATCC 6896
US5773277A (en) 1992-06-26 1998-06-30 Seikagaku Kogyo Kabushiki Kaisha Crystalline chondroitinase isolated from Proteus vulgaris ATCC 6896
US5741692A (en) 1994-04-22 1998-04-21 American Cyanamid Company Protein vulgaris chondroitinase II
US5498536A (en) 1994-04-22 1996-03-12 American Cyanamid Company Chondroitinase II from Proteus vulgaris
US5997863A (en) 1994-07-08 1999-12-07 Ibex Technologies R And D, Inc. Attenuation of wound healing processes
US6093563A (en) 1994-07-08 2000-07-25 Ibex Technologies R And D, Inc. Chondroitin lyase enzymes
JPH09194502A (ja) * 1995-11-13 1997-07-29 Seikagaku Kogyo Co Ltd 新規コンドロイチン硫酸プロテオグリカン、そのコア蛋白質、それをコードするｄｎａおよびそれに対する抗体
EP0875253B1 (de) * 1997-05-02 2005-04-06 Seikagaku Corporation Chondroitinase enthaltende Zusammensetzungen
MXPA01003538A (es) * 1998-10-06 2005-09-08 Rush Presbyterian St Luke Metodo para el tratamiento de quimionucleolisis.
ATE543509T1 (de) * 2001-08-13 2012-02-15 Univ Florida Material und verfahren zur förderung der reparatur von nervengewebe
US7199110B2 (en) * 2002-12-30 2007-04-03 Purdue Research Foundation Method of treatment for spinal cord injury

Also Published As

Publication number Publication date
JP2010132682A (ja) 2010-06-17
SI1480674T1 (sl) 2011-04-29
AU2009200025A1 (en) 2009-02-05
CA2478645C (en) 2011-11-29
IL163884A (en) 2013-01-31
US20050118157A1 (en) 2005-06-02
ATE490786T1 (de) 2010-12-15
AU2003208466A1 (en) 2003-09-16
PT1480674E (pt) 2011-03-15
JP2005526740A (ja) 2005-09-08
CA2478645A1 (en) 2003-09-12
EP1480674A1 (de) 2004-12-01
DE60335244D1 (de) 2011-01-20
WO2003074080A1 (en) 2003-09-12
MXPA04008598A (es) 2005-09-08
ES2357227T3 (es) 2011-04-20
GB0205022D0 (en) 2002-04-17
EP2277531A1 (de) 2011-01-26
AU2009200025B2 (en) 2010-11-18
EP1480674B1 (de) 2010-12-08
AU2003208466B2 (en) 2008-10-02
DK1480674T3 (da) 2011-03-28
HK1073430A1 (en) 2005-10-07
JP5112607B2 (ja) 2013-01-09
IL223875A (en) 2017-02-28

Similar Documents

Publication Publication Date Title
IL163884A0 (en) Treatment of central nervous systemdamage
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
IL188249A0 (en) Cephalosporin related compounds for use in therapy
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
NO20035025D0 (no) Anvendelse av osteopontin for behandling og/eller for å hindre nevrologiskesykdommer
WO2005004814A3 (en) Sirt1 and genetic disorders
ATE237680T1 (de) Transplantation von hämatopoietischen zellen
MXPA05012305A (es) Composiciones y metodos para el tratamiento de lesiones del snc.
MXPA05009986A (es) Tratamiento de la enfermedad de alzheimer.
MXPA05010414A (es) Uso de clusterina para el tratamiento y/o prevencion de enfermedades neurologicas perifericas.
WO2005013911A3 (en) Protective and therapeutic uses for tocotrienols
AU2003304173A1 (en) Compositions and methods for promoting neuronal outgrowth
MXPA05002418A (es) Derivados de 1,4-pirazina sustituidos.
EP1539100A4 (de) Zusammensetzung und verfahren zur behandlung von hauterkrankungen
AUPS255402A0 (en) Agents and methods for the treatment of disorders associated with oxidative stress
AU2003287513A8 (en) Inhibitors of beta-secretase, and their use for the prevention or treatment of alzheimer's disease or mild cognitive impairment
EP1210103A4 (de) Induzierte regeneration und reparatur von beschädigten neuronen und des axonmyelin von nerven
SI1534286T1 (sl) Postopki za zdravljenje ali prepreŽŤevanje avtoimunskih bolezni z 2,4-pirimidindiaminskimi spojinami
WO2005013895A3 (en) Compositions and methods for the treatment of schizophrenia and addictive disorders
UA4678U (uk) Спосіб лікування струсу головного мозку в гострому періоді
MX349462B (es) Composiciones y metodos para el tratamiento de lesiones del snc.
UA32235A (uk) Спосіб моделювання закритої травми нирки в експерименті
UA42301A (uk) Засіб "камілаль" для лікування і профілактики проктологічних захворювань